In the past decade, the emergence of ICIs marked the formal entry of tumor therapy into the immunotherapy phase, and anti-PD-1/PD-L1 antibodies have become one of the most widely used anti-cancer therapies, which are used in the first-line treatment of kidney cancer. The gene discussed is CD274; the disease is kidney cancer.